Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

交易中 07-22 13:01:01 EDT

24.74

-0.34

-1.36%

最高25.12	最低24.40	成交量42.45万
今开25.03	昨收25.08	日振幅2.87%
总市值23.87亿	流通市值23.58亿	总股本9,648万
成交额1,050万	换手率0.45%	流通股本9,531万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":24.74,"timestamp":1721667660641,"preClose":25.08,"halted":0,"volume":424485,"delay":0,"floatShares":95307113,"shares":96475421,"eps":-5.352685,"marketStatus":"交易中","marketStatusCode":2,"change":-0.34,"latestTime":"07-22 13:01:01 EDT","open":25.03,"high":25.12,"low":24.4,"amount":10502711.019855,"amplitude":0.028708,"askPrice":24.77,"askSize":10,"bidPrice":24.74,"bidSize":341,"shortable":3,"etf":0,"ttmEps":-5.352685,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"listingDate":1462507200000,"adjPreClose":25.08,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":25,"preClose":25.08,"latestTime":"09:29 EDT","volume":530,"amount":13273.53889,"timestamp":1721654999909},"postHourTrading":{"tag":"盘后","latestPrice":25.3,"preClose":25.08,"latestTime":"19:57 EDT","volume":38587,"amount":968510.56,"timestamp":1721433432488},"volumeRatio":0.467539,"impliedVol":0.6733,"impliedVolPercentile":0.2749},"requestUrl":"/m/hq/s/NTLA","defaultTab":"news","newsList":[{"id":"2446007110","title":"BUZZ-Alnylam 因心脏病药物在关键研究中获得成功而跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2446007110","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446007110?lang=zh_cn&edition=full","pubTime":"2024-06-25 01:42","pubTimestamp":1719250931,"startTime":"0","endTime":"0","summary":" (更新)    6月24日 - ** Alnylam Pharmaceuticals  股价大涨40%至231.64美元，创下自2023年2月以来的最高水平 。** 如果涨势保持，市值将增加80多亿美元** 该公司称其心脏病药物vutrisiran在一项受到密切关注的后期研究中达到了  主要目标和所有次要目标** 该药物vutrisiran有助于将一种被称为ATTR-CM的罕见心脏病患者的死亡人数和心脏相关住院治疗人数减少33%。** ALNY 公司的药物通过关闭转甲状腺素蛋白的不规则生产而发挥作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","IONS","LU1861558580.USD","BBIO","BK4556","BK4535","LU1861559042.SGD","BK4585","BK4139","BK4588","NTLA","BK4548","ALNY","BK4505"],"gpt_icon":0},{"id":"2440128599","title":"Intellia Therapeutics公布了正在进行的Ntla-2002的1期研究的积极长期数据Ntla-2002是一种用于遗传性血管性水肿（Hae）的在研CRISPR基因编辑疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2440128599","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440128599?lang=zh_cn&edition=full","pubTime":"2024-06-02 20:05","pubTimestamp":1717329953,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics公布了正在进行的Ntla-2002的1期研究的积极长期数据Ntla-2002是一种用于遗传性血管性水肿（Hae）的在研CRISPR基因编辑疗法","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406022005539f11ff88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406022005539f11ff88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRSP","BK4139","LU1861558580.USD","BK4556","LENZ","BK4585","LU1861559042.SGD","BK4588","NTLA","BK4535"],"gpt_icon":0},{"id":"2436945444","title":"Intellia Therapeutics, Inc.2024财年第一财季实现净利润-1.07亿美元，同比减少3.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436945444","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436945444?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:26","pubTimestamp":1715963160,"startTime":"0","endTime":"0","summary":"3月31日，Intellia Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-1.07亿美元，同比减少3.88%；其中营业收入为28.94百万美元，同比增加129.50%，每股基本收益为-1.13美元。从资产负债表来看，Intellia Therapeutics, Inc.总负债2.23亿美元，其中短期债务18.76百万美元，资产负债比为5.66，流动比率为0.10。机构评级：截至2024年3月31日，当前有23家机构对Intellia Therapeutics, Inc.目标价做出预测，其中目标均价为68.17美元，其中最低目标价为24.00美元，最高目标价为144.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180026058b131d6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180026058b131d6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NTLA"],"gpt_icon":0},{"id":"2434855383","title":"美国研究综述-Cerence、Epam Systems、Progyny","url":"https://stock-news.laohu8.com/highlight/detail?id=2434855383","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434855383?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:39","pubTimestamp":1715344798,"startTime":"0","endTime":"0","summary":"    路透5月10日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Cerence、Epam Systems 和 Progyny。要闻  * Cerence Inc   ：富国银行将其评级从 \"增持 \"下调至 \"等权重\"。* Epam Systems Inc   ：丰业银行将其评级从 \"跑赢大市 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFF","GAIN","BK4548","MTRN","GRWG","BK4227","BIGC","GFF","MKSI","CE","EPAM","ARWR","PGNY","ARHS","MRCY","APLT","BRT","GO","FDMT","LU0823414478.USD","LU2463526074.USD","LYFT","LU0053671581.USD","CPAY","CRNX","HLIO","BK4533","OBDC","LU1815336091.USD","LU0320765992.SGD","BK4539","ANIK","CMI","CRL","ACAD","FLNC","FOLD","NTLA","BK4109","HBI","MRC","BK4113","YOU","NTRA","MGNX","OXY","IE00B66KJ199.SGD","AVAH","EYE","FWRD"],"gpt_icon":0},{"id":"2433200845","title":"Intellia Therapeutics Inc    预计每股亏损 1.38 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433200845","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433200845?lang=zh_cn&edition=full","pubTime":"2024-05-07 21:33","pubTimestamp":1715088805,"startTime":"0","endTime":"0","summary":"   * Intellia Therapeutics Inc     5月9日发布的截至2024年3月31日的财报显示，该公司的季度营收预计将出现下降。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司的营收将从去年同期的1261万美元降至1150.4万美元，降幅为8.7%。* LSEG 的分析师平均预计 Intellia Therapeutics Inc 每股亏损 1.38 美元。* 华尔街对 Intellia Therapeutics Inc 的 12 个月目标价中位数为 70.00 美元，高于其最新收盘价 23.72 美元。5月7日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2432970345","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432970345","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432970345?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:30","pubTimestamp":1714743050,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时30分，Intellia Therapeutics, Inc.股票出现波动，股价急速上涨5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Vaxxinity, Inc.、Ardelyx, Inc.、Jaguar Health, Inc.涨幅较大，Allarity Therapeutics, Inc.、Vaxxinity, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为57.88%、20.98%、10.03%，振幅较大的相关个股有Relay Therapeutics, Inc.、Rani Therapeutics Holdings, Inc.、Zymeworks Inc.，振幅分别为13.56%、12.87%、6.37%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032130517925c0a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032130517925c0a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","LENZ","BK4139","LU1861558580.USD","NTLA","BK4535","BK4588","LU1861559042.SGD","BK4585"],"gpt_icon":0},{"id":"2432701185","title":"Intellia Therapeutics, Inc.盘中异动 急速拉升5.02%报22.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432701185","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432701185?lang=zh_cn&edition=full","pubTime":"2024-05-01 21:37","pubTimestamp":1714570679,"startTime":"0","endTime":"0","summary":"北京时间2024年05月01日21时37分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Cytomx Therapeutics, Inc.、Palisade Bio, Inc.、Tg Therapeutics, Inc.涨幅较大，Palisade Bio, Inc.、Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为443.08%、38.73%、15.94%，振幅较大的相关个股有Promis Neurosciences Inc.、Carmell Corporation、Cytomx Therapeutics, Inc.，振幅分别为23.46%、21.50%、19.63%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012137597925a0ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012137597925a0ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU1861558580.USD","BK4556","LENZ","BK4585","LU1861559042.SGD","BK4588","NTLA","BK4535"],"gpt_icon":0},{"id":"2432306173","title":"Intellia Therapeutics Inc    预计每股亏损 1.38 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432306173","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432306173?lang=zh_cn&edition=full","pubTime":"2024-05-01 01:22","pubTimestamp":1714497741,"startTime":"0","endTime":"0","summary":"   * Intellia Therapeutics Inc     预计将在5月2日公布截至2024年3月31日的财报(估计)，季度收入将出现下降。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司的营收预计将从去年同期的1261万美元下降8.7%，至1150.4万美元。* LSEG 的分析师平均预计 Intellia Therapeutics Inc 每股亏损 1.38 美元。* 华尔街对 Intellia Therapeutics Inc 的 12 个月目标价中值为 70.00 美元，高于其上一次收盘价 21.98 美元。4月30日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NTLA"],"gpt_icon":0},{"id":"2431864707","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.06%报21.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431864707","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431864707?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:19","pubTimestamp":1714400366,"startTime":"0","endTime":"0","summary":"北京时间2024年04月29日22时19分，Intellia Therapeutics, Inc.股票出现波动，股价快速拉升5.06%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.99%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042922192687e84c24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042922192687e84c24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4535","BK4588","LU1861559042.SGD","BK4585","LU1861558580.USD","BK4556","BK4139","NTLA"],"gpt_icon":0},{"id":"2430289441","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.03%报20.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430289441","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430289441?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:48","pubTimestamp":1714052918,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时48分，Intellia Therapeutics, Inc.股票出现异动，股价急速下跌5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.37%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425214839861e90d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425214839861e90d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4585","BK4139","LU1861558580.USD","BK4556","BK4535","LU1861559042.SGD","BK4588","NTLA"],"gpt_icon":0},{"id":"2427188660","title":"Intellia Therapeutics, Inc.盘中异动 急速跳水5.03%报23.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427188660","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427188660?lang=zh_cn&edition=full","pubTime":"2024-04-16 00:32","pubTimestamp":1713198756,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日00时32分，Intellia Therapeutics, Inc.股票出现异动，股价大幅下挫5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041600323687e8080e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041600323687e8080e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4556","BK4535","BK4139","BK4585","BK4588","LU1861559042.SGD","LU1861558580.USD","NTLA"],"gpt_icon":0},{"id":"2424049823","title":"Intellia Therapeutics, Inc.盘中异动 急速跳水5.03%报25.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424049823","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424049823?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:50","pubTimestamp":1712065815,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时50分，Intellia Therapeutics, Inc.股票出现波动，股价快速下挫5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.41%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022150157a50b693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022150157a50b693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4535","BK4588","BK4585","NTLA","LU1861558580.USD","LENZ","BK4556","LU1861559042.SGD"],"gpt_icon":0},{"id":"2419986569","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.20%报27.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419986569","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419986569?lang=zh_cn&edition=full","pubTime":"2024-03-14 23:09","pubTimestamp":1710428998,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日23时09分，Intellia Therapeutics, Inc.股票出现异动，股价大幅跳水5.20%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.61%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031423095887e78f8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031423095887e78f8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4556","LU1861559042.SGD","BK4535","CRSP","LU1861558580.USD","NTLA","BK4585"],"gpt_icon":0},{"id":"2417425933","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417425933","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417425933?lang=zh_cn&edition=full","pubTime":"2024-03-06 03:10","pubTimestamp":1709665831,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日03时10分，Intellia Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.48%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030603103179178cc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030603103179178cc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","CRSP","NTLA","BK4556","OCEA","BK4585","BK4535","LU1861558580.USD","LU1861559042.SGD","BK4139"],"gpt_icon":0},{"id":"2416600642","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416600642","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416600642?lang=zh_cn&edition=full","pubTime":"2024-03-01 23:21","pubTimestamp":1709306485,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日23时21分，Intellia Therapeutics, Inc.股票出现异动，股价快速上涨5.20%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.76%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012321257a48980e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012321257a48980e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRSP","LU1861558580.USD","BK4139","BK4556","LU1861559042.SGD","BK4535","BK4588","BK4585","NTLA"],"gpt_icon":0},{"id":"2415552941","title":"Intellia Therapeutics, Inc.盘中异动 早盘快速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2415552941","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415552941?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:48","pubTimestamp":1709218089,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日22时48分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.17%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922480987e74e76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922480987e74e76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","LU1861559042.SGD","NTLA","LU1861558580.USD","BK4556","BK4588","CRSP","BK4585","BK4139"],"gpt_icon":0},{"id":"2414857362","title":"Intellia Therapeutics Inc盘中异动 急速上涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414857362","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414857362?lang=zh_cn&edition=full","pubTime":"2024-02-27 04:27","pubTimestamp":1708979241,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日04时27分，Intellia Therapeutics Inc股票出现波动，股价快速上涨5.10%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.78%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022704272187e73358&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022704272187e73358&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","LU1861558580.USD","BK4556","BK4535","LU1861559042.SGD","BK4588","NTLA"],"gpt_icon":0},{"id":"2414992650","title":"Intellia Therapeutics Inc2023财年实现净利润-4.81亿美元，同比减少1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414992650","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414992650?lang=zh_cn&edition=full","pubTime":"2024-02-26 00:21","pubTimestamp":1708878062,"startTime":"0","endTime":"0","summary":"12月31日，Intellia Therapeutics Inc公布财报，公告显示公司2023财年净利润为-4.81亿美元，同比减少1.48%；其中营业收入为36.28百万美元，同比减少30.39%，每股基本收益为-5.42美元。从资产负债表来看，Intellia Therapeutics Inc总负债2.51亿美元，其中短期债务18.60百万美元，资产负债比为5.19，流动比率为8.68。机构评级：截至2023年12月31日，当前有23家机构对Intellia Therapeutics Inc目标价做出预测，其中目标均价为68.74美元，其中最低目标价为24.00美元，最高目标价为144.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600210681b6075a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600210681b6075a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA"],"gpt_icon":0},{"id":"2413795485","title":"Intellia Therapeutics Inc盘中异动 早盘股价大跌5.04%报25.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413795485","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413795485?lang=zh_cn&edition=full","pubTime":"2024-02-24 00:14","pubTimestamp":1708704846,"startTime":"0","endTime":"0","summary":"北京时间2024年02月24日00时14分，Intellia Therapeutics Inc股票出现异动，股价大幅下挫5.04%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.56%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224001406861d7f32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224001406861d7f32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","BK4139","BK4556","LU1861559042.SGD","BK4535","BK4588","BK4585","NTLA"],"gpt_icon":0},{"id":"2413719217","title":"Intellia Therapeutics Inc盘中异动 早盘大幅跳水5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413719217","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413719217?lang=zh_cn&edition=full","pubTime":"2024-02-22 23:21","pubTimestamp":1708615266,"startTime":"0","endTime":"0","summary":"北京时间2024年02月22日23时21分，Intellia Therapeutics Inc股票出现波动，股价急速下挫5.02%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.75%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022223210687e72484&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022223210687e72484&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4535","BK4139","BK4585","BK4588","LU1861559042.SGD","LU1861558580.USD","NTLA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":0.0113},{"period":"3month","weight":0.1627},{"period":"6month","weight":-0.0184},{"period":"1year","weight":-0.4205},{"period":"ytd","weight":-0.1774}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.014871},{"month":2,"riseRate":0.75,"avgChangeRate":0.078068},{"month":3,"riseRate":0.25,"avgChangeRate":-0.040105},{"month":4,"riseRate":0.375,"avgChangeRate":-0.074095},{"month":5,"riseRate":0.25,"avgChangeRate":0.030737},{"month":6,"riseRate":0.888889,"avgChangeRate":0.214578},{"month":7,"riseRate":0.555556,"avgChangeRate":0.016724},{"month":8,"riseRate":0.625,"avgChangeRate":0.047366},{"month":9,"riseRate":0.125,"avgChangeRate":-0.068112},{"month":10,"riseRate":0.25,"avgChangeRate":-0.059832},{"month":11,"riseRate":0.625,"avgChangeRate":0.121561},{"month":12,"riseRate":0.375,"avgChangeRate":-0.073139}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}